The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive
symptoms in women with Major Depressive Disorder (MDD) and antidepressant
partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women
with MDD and antidepressant partial/nonresponse, and low-dose testosterone augmentation
improves fatigue and sexual dysfunction.
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Lawley Pharmaceuticals National Institutes of Health (NIH)